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Abstract
Background: Due to the low participation in colorectal cancer screening, public preference for
colorectal cancer screening modality was determined.
Methods: A cross-sectional survey was performed of healthy ambulatory adults in a pediatrics
primary care office and neighboring church. Overall preference was ranked for each of four
colorectal cancer screening modalities: Faecal Occult Blood, Fiberoptic Sigmoidoscopy, Barium
Enema and Colonoscopy. Four additional domains of preference also were ranked: suspected
discomfort, embarrassment, inconvenience and danger of each exam.
Results:  80 surveys were analyzed, 57 of which were received from participants who had
experienced none of the screening tests. Fecal Occult Blood Testing is significantly preferred over
each other screening modality in overall preference and every domain of preference, among all
subjects and those who had experienced none of the tests.
Conclusions: Efforts to increase public participation in colorectal cancer screening may be more
effective if undertaken in the context of public perceptions of screening choices.
Background
Screening for colorectal cancer lessens the risk of dying
from that disease [1]. Knowledge of this fact has not
solved all the problems related to screening. The optimal
modality of screening is still the subject of debate [1-3].
More problematic is the very low participation of the gen-
eral public in recommended screening [4]. In contrast to
breast cancer screening, in which the Healthy People 2000
Goal of the U.S. National Institutes of Health was sur-
passed, at 64% participation by women over 40 years of
age, only 20% of Americans over age 50 had fecal occult
blood testing within the past year (This is the best esti-
mate of actual screening, rather than diagnostic endeavors
for symptoms for which endoscopy or radiologic imaging
might be done.), and 34% had a sigmoidoscopy within
the past 5 years [5,6] Even if screening is appropriately
performed, it is far from certain that a positive screen will
be followed by appropriate diagnostic testing, as has been
shown in follow-up surveys of fecal occult blood testing
[7].
Most publication concerning colorectal cancer screening
relates to the choice of screening modality; discussing
accuracy, efficacy and cost, since the most inexpensive
technique, faecal occult blood testing, is inaccurate in the
detection of colorectal neoplasia, though effective in
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significantly diminishing disease specific mortality [8],
and the most accurate technique, colonoscopy, is expen-
sive and not without danger [3]. The choice is not an easy
one for clinicians, much less patients or the asymptomatic
public. Therein may lie one of the problems with public
participation in screening. Unlike cancers of the breast,
cervix, prostate or lung, where a single screening modality
dominates current recommendations for each, there are
four different and relatively independent screening tests
for colorectal cancer that are currently recommended by
the American Cancer Society, National Cancer Institute
and United States Preventative Services Task Force: faecal
occult blood test (FOBT), fiberoptic sigmoidoscopy (FS),
barium enema (BE), and colonoscopy (C) [1]. The
absence of a single recommendation may lead from inde-
cision to inaction on the part of clinicians or patients.
However the greatest problem related to screening
remains the low level of participation by those for whom
it is intended: asymptomatic individuals over the age of
50 years with no specific risk factors for colorectal cancer,
i.e., no past history of colorectal polyps, cancer, rectal
bleeding, colitis, change in bowel habits, iron deficiency
anemia, weight loss or a close family member with color-
ectal cancer. We agree with Dr. Woolf [2], that strategies to
improve public compliance with recommended colorec-
tal cancer screening might be more effective if they include
an awareness of what the public thinks about the tests
being recommended. Previous studies have not surveyed
asymptomatic participants' preference over the whole
range of screening choices, focusing instead on sympto-
matic patients undergoing diagnostic evaluation such as
colonoscopy and barium enema [9-11] or patients ailing
from extracolonic diseases whose motivation for screen-
ing might be very different than the healthy population
for whom screening is intended [12-18]. Among these lat-
ter studies there has been a general preference noted for
FOBT (table 1).
We have in this report chosen to focus our survey differ-
ently and uniquely; first to inform healthy, ambulatory
and younger people, and not ailing patients, concerning
only the preparation and conduct of each screening test.
Secondly, in order to determine how their perceptions of
the conduct of each test might affect their participation,
participants were then asked to rank not just their overall
preference based upon the preparation and conduct of the
tests alone, but four other domains of preference for each
screening modality: perceived physical discomfort, incon-
venience, embarrassment and danger. Test accuracy was
not included in the preamble on test performance, first,
because we wanted to isolate perceptions of the physical
conduct of the screening test, and second, because test
accuracy has been part of many of the previous surveys,
often presented with considerable bias. Randomized trials
of decision aids have also shown that description of a
test's ability to detect colorectal cancer has not been suc-
cessful in increasing participation in screening [15-17].
Lastly, despite the current enthusiasm for screening colon-
oscopy by organizations that do colonoscopy as the com-
plete screening test [19], as mentioned above, the choice
of screening modality is still regarded as controversial.
Methods
Participants were a convenience sample of parents or
grandparents of children visiting a general pediatrics
office (usually for well child visits or minor ailments), per-
sonnel working in that office, or parishioners attending a
church social gathering, all aged 18 and over. An introduc-
tory letter described the purpose of the survey. This was
followed by a brief description of the preparation and per-
formance of each commonly used screening test for color-
ectal neoplasia: faecal occult blood testing (FOBT),
fiberoptic sigmoidoscopy (FS), air contrast barium enema
(BE) and total colonoscopy (C). The relative accuracy of
each exam was not discussed. Six questions followed. The
first asked the participant to rank each test in order of
overall preference. The second asked the participant to
rank each test according to how much that test might
cause physical discomfort, the third, inconvenience; the
fourth embarrassment, the fifth, the relative danger of the
exam. The sixth question asked participants which of the
four tests they had previously experienced, along with
their gender and age. No further symptom or medical his-
tory was obtained and surveys were only numbered con-
secutively with no personal identifiers. (see appendix for
letter and survey)
Based upon a related survey concerning subject preference
for tests of colonic inflammation [20], a sample size of 50
individuals was estimated. Eighty four questionnaires
were distributed in order to assure receipt of an adequate
number of usable responses from individuals who had
experienced none of the screening tests. The questionnaire
is shown in the Appendix.
Analyses
Data were analyzed using SPSS 11.0. Analyses focused on
comparisons between ranks assigned each test on prefer-
ence and the other assessed attributes, and included Fried-
man's test for ranks (to test the hypothesis that ranks
differed for different tests) and the Wilcoxon signed-ranks
test (to test the hypothesis that pairs of tests were differ-
ently ranked.) We also considered whether those rank
orders might differ between participants who have and
have not received any of these tests, and how gender and
age affected preferences.BMC Cancer 2004, 4:76 http://www.biomedcentral.com/1471-2407/4/76
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Results
80 of 84 surveys were available for analysis; twenty nine
from men and 51 from women. The mean age of the par-
ticipants was 38.3 years (range 18 – 54 years; St. Dev. 8.19
years; median 40 years). Eight subjects had previously had
a colonoscopy, five a barium enema, seven a sigmoidos-
copy and 17 had stool collected for various reasons. Fifty
seven subjects had experienced none of the screening
tests. The mean rankings for preference among the entire
sample are presented in Table 2 and among only those
individuals who had experienced none of the tests are pre-
sented in the Table 3, score "1" being the most preferred
Table 1: Surveys of screening preference for colorectal cancer
First Author Subjects Age Range N = Comparison Preference Comment
Steine9 GI Patients 45–79 y 190 BE v C BE Post hoc
Durdey10 GI Patients 19–88 y 66 BE v C C Post hoc
VanNess11 GI Patients 20–84 y 189 BE v C C Post hoc
Elwood20 Relatives of GI Patients 45–70 y 232 FS v C FS = C RCT; Subjects offered FS or C and differential 
compliance measured
Dominitz12 VAOP 50–75 y 62 FS v C FS Time trade off measure Least for FS.
Frew13 PCOP >25 y 2294 FOBT v FS FOBT Willingness to pay primary endpoint. Preference 
also collected.
Leard14 PCOP 50–75 y 100 FOBT, FS, BE, C C preferred 
FOBT more likely 
to be done.
Post hoc 93% previously screened
Dolan17 PCOP >50 y 96 FOBT, FS, BE, C FOBT DARCT
Pignone15 PCOP 50–75 y 227 FOBT v FS FOBT DARCT
Pignone18 PCOP 50–75 y 146 FOBT v FS FOBT 4 levels of survey after varying quantities of 
information on colon cancer risk, conduct, test 
accuracy, cost.
Wolf16 PCOP >65 y 57 FOBT v FS FOBT DARCT
Nelson Non-patients 18–54 y 80 FOBT, FS, BE, C FOBT
GI Patients; Gastroenterology patients
BE; Barium enema.
C; Colonoscopy
FS; Fiberoptic sigmoidoscopy
FOBT; Fecal Occult Blot Testing
Post hoc; Preference measured after undergoing one or more of the above screening tests.
RCT; Randomised Controlled Trial
VAOP; Veteran's administration hospital outpatients
PCOP; Primary care outpatients
DARCT; Randomised trial to investigate the effectiveness of decision aids in increasing screening participation
Table 2: Mean test ranks for each domain of preference of colorectal cancer screening test
Dimensions
Test Modality Preference Physical 
Discomfort
Inconvenience Embarrassment Danger
Colonoscopy 3.14 3.37 3.47 3.14 3.56
Barium Enema 2.87 3.09 2.97 3.12 3.56
Fiberoptic Sigmoidoscopy 2.38 2.46 2.04 2.40 2.32
Fecal Occult Blood Test 1.61 1.09 1.52 1.34 1.09
Friedman's test χ2 (3 df) 62.7* 146.6* 110.9* 102.4* 162.8*
Wilcoxon signed-ranks Z (FOBT vs. FS) 4.1* 7.2* 3.2* 5.3* 7.5*
N  = 7 77 97 97 87 9
Notes: Mean ranks for each test on each of the dimensions. Lower mean ranks refer to greater preference, and less discomfort, inconvenience, 
embarrassment, or danger. A * indicates test statistics that are significant at p < 0.05.
N = ; Less than 80 responses due to blank forms.BMC Cancer 2004, 4:76 http://www.biomedcentral.com/1471-2407/4/76
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and "4" the least. In each case, mean rankings were found
to vary by test (Friedman's test, 3 df), and FOBT was sig-
nificantly preferred over the second-ranked test (FS) by
Wilcoxon signed-ranks test.
Median scores were determined for each domain for both
the whole survey group and the naive subgroup. For each
domain and in each group the results were the same, with
ranks of 4,3,2 &1 for C, BE, FS and FOBT respectively, 1
being most preferred, except for embarrassment in both
groups in which C and BE each had a median rank 3.
The results hold up for each gender subgroup in all cases
except that men didn't consider FOBT significantly less
inconvenient than FS. Age was not significantly correlated
with ranking of FOBT (that is, the ranking given didn't
change with age) by Spearman's rho. Rho values ranged
from -0.10 to +0.16, none significant. Splitting the groups
into ages 18–39 (n = 39) and 40+ (n = 40), the results are
the same for both groups except that for those over 40,
preference for FOBT vs. FS and inconvenience of FOBT vs.
FS did not reach significance by two-tailed test (p = .079
and p = .057 respectively)
Discussion
A recent review of colorectal cancer screening stated that,
"At present there is no preferred CRC screening strat-
egy"[1]. This presents the perspective of a group of impar-
tial physicians. However from the perspective of those
who should take part in CRC screening in the future, a
clear preference for FOBT over each other screening
modality is expressed in this survey. Each domain of pref-
erence similarly ranks FOBT as significantly most
preferred.
Among previous surveys there are four randomized con-
trolled trials of the use of decision aids that were designed
with the intent of altering participation in screening.
Three of these presented choices of screening modality or
scenario to both intervention and control groups [15-17].
These studies therefore provided information of partici-
pant preference for specific screening modality, though
again the participants, primary care patients, were quite
different from the group reported herein. Only one of
those reports offered all four of the screening modalities
that we did in our study [16], the other two offering only
a choice between FOBT and FS [15,16]. Nevertheless a
uniform preference for FOBT was reported in these studies
as well (Table 1). None of the test interventions were par-
ticularly effective in increasing participation in screening,
an endpoint not assessed in our study. The fourth rand-
omized trial randomized non-patients, relatives of gastro-
enterology patients, to be offered either FS or C and
measured differential participation, which was equal in
the two groups [20]. In the survey most similar to the
present study, Pignone surveyed 146 patients in a general
medicine clinic [18] and questioned participants after
four sequential levels of information were given. Only
two screening options were presented, FOBT & FS. Infor-
mation included in sequence 1) the risk of colorectal can-
cer, 2) description of the conduct of the test, 3)accuracy of
the tests, 4) cost. Previous screening participation was
queried but not an exclusion. Less than 5% of those
approached refused participation and no data were pre-
sented on the screening naïve participants in his sample.
FOBT was preferred at each level of investigation, though
both tests together were preferred after level 2 (Table 1).
Participants were also asked for reasons for their prefer-
ences. The reasons most often given related to cost, ease of
performance and being done alone.
Table 3: Mean test ranks for each domain of preference of colorectal cancer screening test:: individuals who have experienced none of 
the tests
Dimensions
Test Modality Preference Physical 
Discomfort
Inconvenience Embarrassment Danger
Colonoscopy 3.13 3.42 3.56 3.07 3.57
Barium enema 2.83 3.11 2.98 3.15 3.05
Fiberoptic sigmoidoscopy 2.35 2.45 1.91 2.38 2.32
Faecal occult blood test 1.69 1.02 1.55 1.40 1.05
Friedman's test χ2 (3 df) 38.7* 112.6* 86.6* 65.9* 118.4*
Wilcoxon signed-ranks Z (FOBT vs. FS) 3.2* 6.5* 2.0* 4.3* 6.6*
N  = 5 45 55 55 45 5
Notes: Mean ranks for each test on each of the dimensions. Lower mean ranks refer to greater preference, and less discomfort, inconvenience, 
embarrassment, or danger. A * indicates test statistics that are significant at p < 0.05.
N = ; Less than 57 due to blank responsesBMC Cancer 2004, 4:76 http://www.biomedcentral.com/1471-2407/4/76
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Among some physicians there is a growing popularity for
the use of definitive diagnostic testing as a screening tool,
that is, colonoscopy [19]. Though expensive and not with-
out danger, reimbursement for the test is declining and
the procedure is getting safer. It has obvious theoretical
advantages of offering precise diagnostic capabilities,
through biopsy, for those with positive screens. Most
important, colonoscopy has the best potential for cancer
prevention by adenoma removal – which is not possible
with any other test [22,23]. This, properly applied, might
even result in cost savings in the global cost of caring for
colorectal cancer.
But the public has to want to participate in this program
and there is little evidence in this current survey and pre-
vious studies, especially those done in primary care set-
tings [13-18], that this is likely. The concerns expressed
herein about safety, embarrassment, inconvenience and
discomfort all must be addressed in future efforts to
increase screening participation. A potentially significant
development related to these issues is that the principal
disadvantage of FOBT, its inaccuracy in detecting colorec-
tal neoplasia, might be overcome. Recently developed
stool tests show an ability to diagnose cancer with much
greater reliability [24]. Perhaps these gene based stool
tests may establish the potential for adenoma discovery by
non-invasive testing as well.
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